FDA Cleared

We pride ourselves in working with the FDA to ensure safety and reliability for end customers.

Athelas was granted a FDA 510K Class 2 clearance for the Athelas One device. The system is cleared for point-of-care indications in the evaluation of WBC and NEUT%.


Clinically Validated

We take accuracy and transparency seriously. Read our third-party clinical white paper on the accuracy of our capillary WBC and Neutrophil results versus venous blood samples on the Sysmex XE-5000.

Blood: Clinical Third Party Validation of the Athelas Device

View Publication
November 29, 2018

Ann. Clinical Psychiatry - Athelas and Clozapine

View Publication
May 1, 2021

FDA 510K Clearance Studies

View Publication
November 5, 2018

Athelas One Clozapine Cost Savings

View Publication
June 6, 2020

Start earning revenue with Athelas today

Practices use Athelas to deliver remote care programs and increase their revenue.

Get a free demo